Dialogues

Oct 7, 2024, 19:42

ASCO24 Updates – Dimitra Rafailia Bakaloudi: Urothelial Carcinoma Insights at ASCO 2024

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Dimitra Rafailia Bakaloud, a postdoctoral researcher at the University of Washington, shares insights from ‘Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).‘

Hello, my name is Dimitra Bakaloudi and I’m working as a postdoctoral researcher at the University of Washington. Today I’m excited to talk about our project we submitted at the ASCO annual meeting 2024. At the University of Washington we have a multi-institutional database that includes patients with urothelial carcinoma who were treated with immune checkpoint inhibitors.

In our latest project we try to examine the responsive outcomes of patients with urothelial carcinoma mixed with subtype histology who were treated with immune checkpoint inhibitors and examine if there is a difference between pure urothelial carcinoma and patients with mixed histology.

We did not find any significant difference regarding the survival outcomes, overall survival and progression from pre-survival in patients with urothelial carcinoma mixed with subtype histology but we found a numerically higher response rate in patients with urothelial carcinoma mixed with sarcomatoid histology and in patients with urothelial carcinoma mixed with more than two subtype histologies. Of course we acknowledge all the limitations of our study including the retrospective design and the fact that for some subsets the sample size was limited.

Thank you so much.

More videos and content from ASCO 2024 on OncoDaily.